Complex edema of soft tissues that is poorly localized, provoking point disturbances in the blood supply system and accompanied by painful sensations is a rather serious challenge for the pharmaceutical industry. Injuries of this kind are most often the result of surgical and postoperative interventions or the result of mechanical damage to the musculoskeletal system, the brain and / or spinal cord (volumetric hematomas, complications in the form of progressive swelling, etc.).

High-quality therapy and effective prevention of edematous pain syndrome is the "sphere of responsibility" of diuretics, glucocorticoids, flavonoids, ergot alkaloids, as well as medicines obtained from the fruits of ordinary horse chestnut. In the latter case, of particular interest is "Lysina escinat", whose analogues, despite the similarity of the pharmacological action algorithm, sometimes cannot provide the necessary therapeutic effect.

The body's response to an active substance

The instruction for use classifies "Lysina escinat" as a multifunctional angioprotector. The components of the drug, reacting with the cells of the body, reduce the likelihood of developing large-scale inflammation, extinguish the sensitivity of pain receptors and slow down the progress of edema in the tissues (up to a complete stop of exudative processes).

This result is possible due to the inhibition of lysosomal hydrolases, which are responsible for the rate of degradation of mucopolysaccharides inside the bloodstream and in the adjacent connective tissues. Moderate hypoglycemic manifestations and a general increase in vascular tone against the background of normalization of their permeability is a natural result of the dosed use of this medication.

Indications for prescribing a medicinal product

"Lysine escinat" (the instruction presents it as one of the forms of a composite combination of horse chestnut triterpene saponins) is prescribed by prescription if:

diagnosed with swelling of the brain / spinal cord of severe and critical development (including when the presence of intracranial hematomas with displacement is confirmed);
local edema of soft tissues was found, which affects the work of the musculoskeletal system (the patient has acute pain during movement / physical exertion, and the damaged parts of the body are supplied with blood in an atypical mode);
suspicions regarding acute thrombophlebitis were justified (there is an imbalance in the venous circulation of the legs, further aggravated by edematous-inflammatory processes).

The use of the medication implies a leisurely one (the setting of an intra-arterial dropper is strictly prohibited). The optimal daily dose for adults is 5-10 ml of the drug diluted with 0.9% sodium chloride solution (NaCl volume - 15-50 ml). However, in cases of a real threat to the patient's life (as a rule, with progressive ones, it is permissible to increase the daily norm to 20 ml of active substance (two doses within 24 hours, 10 ml each). The maximum dose is 25 ml / day.

For pediatric patients "Lysine escinat" the instruction predetermines the introduction in the following quantities:

child age 1-5 years: 0.22 mg per kilogram of body weight;
age 5-10 years: 0.18 mg / kg;
age 10-15 years: 0.15 mg of the drug per kg;
age 15-18 years: 0.12 ml / kg.

The preparation of the active solution, that is, the dilution of the medication should be done immediately before use. The total duration of therapy should not exceed 8 days (the course can be shortened to two days if the attending physician considers that the patient's condition has stabilized earlier than the specified time).

Clinical trial results

"Lysina escinat" instructions for use are positioned as a drug that has passed clinical trials and has demonstrated high efficiency in the fight against edema of various origins. So, in particular, in patients with a traumatic brain tumor after administration of the medication through a dropper, a significant reduction in the area of \u200b\u200binflammation was observed. Along the way, the structure of the edema also changed: the intact areas ceased to shrink, which contributed to the acceleration of the pressure stabilization inside the cranium. It was also noted that timely injections of "Lysine escinat", performed in the form of a smooth infusion with a delayed injection, often prevented the development of the above scenarios and had a beneficial effect on the patient's well-being.

Suppression of inflammatory reactions at the initial stage and prevention of volumetric swelling is reflected in the stimulation of the functional activity of the brain, that is, in minimizing the regression of nerve endings.

Special conditions of use

Despite the fact that the reviews of specialized specialists about the drug "Lysina escinat" are predominantly positive, there is no reliable information on the reaction of active components to the fetus during pregnancy (a similar situation is with breastfeeding of newborns). Therefore, it is not recommended to prescribe a drug in such cases.

In addition, special attention should be paid to patients with a diagnosis of hepatocholecystitis - escinate plays the role of a natural catalyst for transaminases and can slightly load the liver. However, in the absence of other pathologies, this disease is not a reason for discontinuing the drug.

Side effects and contraindications

In addition to pregnancy and lactation, the instructions for use impose the following prescription restrictions on the drug "Lysina escinat":

individual intolerance to the components;
serious problems in the liver;
internal bleeding (ulcers or other forms of erosion of organs and tissues).

Subject to the above conditions, the drug is extremely rare. And yet they are not excluded:

skin integument: itching, urticaria, the formation of bright "blush" on the face;
nervous system: tremor alternating with convulsions, acute persistent headaches, fainting;
Gastrointestinal tract: nausea, sometimes - diarrhea and vomiting;
biliary system and liver: short-term increase in the activity of bilirubin and transaminases;
blood vessels and heart: hypotension and hypertension, arrhythmia;
respiratory organs: shortness of breath, severe dry cough.

Quite often, side effects are poorly expressed, which makes it difficult to diagnose allergies. For example, general weakness or fever can be perceived not as a result of intravenous drug intake, but as a result of a cold.

The nature of interaction with other medications

"Lysina escinat" (patient reviews about this medicine, as a rule, are reduced to the topic of complications in the work of the musculoskeletal system, since they cannot assess the therapeutic effect in brain injuries, due to the criticality of the situation) refers to alcohol-containing compounds. Therefore, it is necessary to select drugs for simultaneous use in course therapy with increased caution (alkaloids can neutralize active substances).

Contact of escinat with aminoglycosides is undesirable. The reason lies in the increased toxicity of the reagents. The presence of anticoagulants in the prescription forces us to revise the dosage of the drug in the direction of decreasing the daily rate. But the combination with analgesics and antimicrobial agents is going well (the anti-inflammatory properties of escinat are enhanced against the background of the absence of additional loads on organs and systems).

Release form and description

As a representative of the group of angioprotectors, the drug "L-lysine escinat", reviews of which are sometimes subjective and do not reflect the real picture of what is happening, is produced in the form of a clear, colorless solution. In this case, 1 ml of liquid contains 0.001 g of active substance. The role of auxiliary components is assigned to propylene glycol, ethyl alcohol and specially prepared (injection) water.

A quick overview of alternative drugs

The trade name of the described medicine is "Lysina escinat".

Analogs similar in pharmacological action are presented below:

Furosemide (tablets / solution) - fight against edema-pain syndrome in hereditary diseases of the cardiovascular system, elimination of swelling in the areas of the brain / spinal cord (hematomas of a mechanical nature of origin), stimulation of diuresis, etc.
"Hypothiazide" (tablets) - with edema, provoked by congenital heart failure, cirrhosis, hypertension.
Valusal (tablets / capsules / cream / solution) - for localization and neutralization of musculoskeletal degenerative processes, relief of postoperative pain syndrome, etc.

"Lysina escinat": reviews of doctors and patients

Edema of interhemispheric tissues and swelling of the brain matter are evidence of severe traumatic brain injury. According to experts, in such a situation, the structural displacement of areas of the cortex, which entails disability or death, is a matter of several hours, and sometimes minutes. Dehydration therapy is usually done to stabilize the situation. However, corticosteroids, saluretics and osmotics - the most common “tools” of exposure - often provoke side effects or do not justify their hopes at all.

According to practicing neurosurgeons, Lysina escinat should become an alternative drug (instructions, expert reviews and important nuances regarding the method of using the drug are given above). Unlike analogs, the injection solution does not cause critical complications and precisely hits the target, thereby ensuring control of the dynamics of swelling (minimizes the volume of swelling of the brain / spinal cord).

L-Lysina Escinat: instructions for use

Structure

1 ml of solution contains L-lysine aescinat (in terms of 100% substance) 0.001 g,

excipients: ethyl alcohol 96%, propylene glycol, water for injection.

Description

clear, colorless solution;

pharmachologic effect

The drug has anti-inflammatory, decongestant and analgesic effects. Escin lowers the activity of lysosomal hydrolases, which prevents the breakdown of mucopolysaccharides in the walls of capillaries and in the connective tissue that surrounds them, and thus normalizes increased vascular tissue permeability and has antiexudative (decongestant), anti-inflammatory and analgesic effects. The drug increases vascular tone, has moderate immunocorrecting and hypoglycemic effects.

Indications for use

Post-traumatic, intra- and postoperative edema of any localization: severe edema of the brain and spinal cord, including with subarachnoid and intracranial hematomas and displacement of the midline structures of the brain and edema-swelling syndrome; edema of soft tissues with the involvement of the musculoskeletal system, accompanied by local disorders of their blood supply and pain syndrome; edematous pain syndromes of the spine, trunk, extremities; severe violations of the venous circulation of the lower extremities in acute thrombophlebitis, accompanied by edematous-inflammatory syndrome.

Contraindications

The drug is contraindicated in patients with severe impaired renal function, as well as in individuals with increased individual sensitivity to the components of the drug. Children under 1 year old.

Method of administration and dosage

The daily dose for adults is 5-10 ml. 5-10 ml of the drug is diluted in 15-50 ml of sodium chloride ", 0.9% solution for injection and injected only intravenously (intra-arterial administration is not allowed). In conditions that threaten the patient's life (acute traumatic brain injury, intra- and postoperative edema of the brain and spinal cord with symptoms of edema-swelling, large swelling due to common injuries of soft tissues and musculoskeletal system), the daily dose is increased to 10 ml twice per day. The maximum daily dose for adults is 25 ml.

The duration of the drug is 2-8 days, depending on the effectiveness of therapy.

Have childrena single dose is administered at the rate of: 1-5 years old - 0.22 mg of L-lysine aescinat per kg of body weight; 5-10 years - 0.18 mg L-lysine aescinat per kg of body weight; 10 years and older - 0.15 mg L-lysine aescinat per kg of body weight; over 10 years old - 0.12 mg L-pisin aescinat escin per kg of body weight. The drug is administered 2 times a day. The duration of the course is from 2 to 8 days, depending on the patient's condition and the effectiveness of therapy.

Side effect

With individual sensitivity of escin in some patients, allergic reactions are possible in the form of a skin rash, urticaria, angioedema.

Interaction with other medicinal products

In the treatment of L-lysine with scinate, it is possible to prescribe other drugs if indicated (anti-inflammatory, analgesics, antimicrobial). The drug should not be used simultaneously with aminoglycosides because of the possibility of increasing their nephrotoxicity. If it is necessary to simultaneously prescribe L-lysine aescinat and anticoagulants, the doses of the latter should be reduced (control of the prothrombin index). The binding of escin to plasma protein is impaired by the simultaneous use of cephaposporin antibiotics, which can increase the concentration of free escin in the blood with a risk of development side effects the latter.

Application features

In some patients with hepatocholecystitis, when the drug is prescribed, a short-term increase in transaminase activity is possible, which does not constitute a threat to patients and does not require discontinuation of the drug. There is no experience of use in pregnant women and in women during lactation.

Release form

10 ampoules of 5 ml per box.

Storage conditions

Store out of the reach of children, protected from light, at temperatures from + 15 ° C to + 25 ° C.

Shelf life

2 years.

Terms of dispensing from pharmacies

On prescription.

Self-medication can be harmful to your health.
It is necessary to consult a doctor, and also read the instructions before use.

Read the official instructions for use of the drug Lysine in an abridged version. It includes: composition, action, contraindications and indications for use, analogues and reviews. The text is provided for informational purposes only and cannot serve as a substitute for a doctor's advice.

Lysine is essential amino acid, contributing to the regulation of the pineal gland, mammary glands and ovaries. It is essential for the growth and development of bones; helps the absorption of calcium; maintains nitrogen balance; participates in the production of antibodies, hormones and collagen; promotes the formation of muscle tissue.

Composition and release form of the drug Lysine

Release form: Liquid dosage forms. Injection.

The composition of the product

1 ml of solution includes active substance L-lysine aescinat (in terms of 100% substance) 0.001 g;
other components: ethyl alcohol 96%, propylene glycol, water for injection.

Instructions for the use of lysine

The daily therapeutic dose of lysine

Most people do not require lysine supplements. For the treatment of herpes, 1000-1300 mg of lysine per day is recommended.

Lysine deficiency symptoms

Symptoms and signs of lysine deficiency include anemia, apathy, bloodshot eyes, depression, swelling, fatigue, febrile herpes, hair loss, distraction, infertility, irritability, lethargy, liver damage, loss of vitality, loss muscle mass, stunted growth, stomach ulcers and weakness.

Maximum safe lysine content

Not installed. However, lysine supplements should not be taken for more than six months, as longer use can cause an imbalance in the amino acid arginine.

Indications, contraindications, side effects from the use of lysine

Indications for the use of lysine

Several studies have shown that regular use of lysine supplements can reduce the frequency and intensity of sudden outbreaks of cold sores. After the initial infection with a herpes infection, the virus hides in nerve cells and triggers disease outbreaks at times of stress, such as when the body is exposed to an immune hazard.

In vitro studies suggest that lysine fights the herpes virus by blocking the action of arginine, which the herpes virus needs to reproduce. Walsh and others studied data from a study of 1,543 men and women six months after starting lysine supplementation, who were diagnosed with herpes, gangrenous ulcers, and genital herpes. 84% of participants reported that lysine supplementation prevented recurrent outbreaks or reduced the incidence of herpes infections. 79% of participants described their symptoms as severe or intolerant without lysine supplementation, and only 8% said symptoms persisted while taking lysine.

What's more, it is likely that lysine also promotes faster wound healing: 90% of participants reported that it took six to fifteen days to heal, but with lysine supplements, 83% of participants reported that their wounds healed in five days or less. Overall, 88% of participants considered lysine supplementation to be an effective form of treatment for herpes infection.

Animal studies show that dietary supplements with various amino acids - in particular, lysine - can increase calcium absorption. Civitelli and colleagues18 found that lysine can increase both intraintestinal calcium absorption and renal retention of assimilated calcium. Together, these actions promote a positive calcium balance; Civitelli suggests lysine supplementation may help prevent and treat osteoporosis.

Side effects and contraindications of taking the amino acid lysine

People who are allergic to eggs, milk, or wheat should not take lysine supplements.
People with liver or kidney disease should consult their physician before taking lysine supplements.

Natural sources of lysine are beans, brewer's yeast, cheese, dairy, eggs, fish, molasses, meat, milk, nuts, potatoes, seafood, seeds, soy, whey, whole grains, and yeast.

Galichpharm, PJSC

Country of origin

Ukraine

Product group

Medical

Selling features

A drug with venotonic and angioprotective action

Release forms

5 ml - ampoules (5) - contoured cell packs (2) - cardboard packs.

pharmachologic effect

L-lysine escinate reduces the activity of lysosomal hydrolases, which prevents the breakdown of mucopolysaccharides in the walls of capillaries and in the connective tissue that surrounds them, and thus normalizes increased vascular tissue permeability and has an anti-exudative (decongestant) and analgesic effect. The drug increases vascular tone, has a moderate hypoglycemic effect.

Pharmacokinetics

Has not been studied.

Special conditions

In some patients with hepatocholecystitis, when the drug is prescribed, a short-term increase in the activity of transaminases and bilirubin (direct fraction) is possible, which does not pose a threat to patients and does not require discontinuation of the drug. The concentrate for the preparation of a solution for intravenous administration contains 23.8% ethanol by volume, that is, up to 2.4 ml of ethanol in a single dose and a maximum of 6.1 ml /, which corresponds to 122 ml of beer or 50.8 ml of wine per day. The drug should be prescribed with caution in alcoholism, as well as in patients with liver disease and epilepsy. Influence on the ability to drive vehicles and control mechanisms The use of the drug can affect the ability to drive vehicles and mechanisms, but due to the severity of injuries in which the use is indicated, this factor usually does not matter.

Structure

Active ingredient: L-lysine escinate - 1.0 mg. Excipients: ethanol 96% - 200.0 mg, propylene glycol - 200.0 mg, water for injection - up to 1 ml.

L-Lysine escinat indications for use

- post-traumatic and postoperative edema of soft tissues of various localization; - edema of the brain or spinal cord of traumatic or postoperative origin; - Violations of the peripheral venous circulation, accompanied by edema.

L-Lysine escinat contraindications

- severe renal dysfunction; - severe liver dysfunction; - bleeding; - children up to age 18; - pregnancy; - lactation period; - hypersensitivity to L-lysine aescinat and / or other components of the drug.

L-Lysine escinate dosage

The drug is administered strictly intravenously slowly, as a rule, by drip (intra-arterial injection is not allowed) in a daily dose of 5-10 ml. To prepare the infusion solution of L-lysine, the escinat is diluted in 50-100 ml of 0.9% sodium chloride solution. If necessary, the drug can be injected in / in a jet very slowly. For intravenous injection of L-lysine, escinat is diluted in 10-15 ml of 0.9% sodium chloride solution. The drug is not used without preliminary dilution. In conditions that threaten the patient's life (traumatic brain injury, postoperative edema of the brain and spinal cord with symptoms of edema-swelling, large swelling due to extensive soft tissue injuries), the daily dose is increased to 20 ml, divided into 2 doses. The duration of the course of treatment is from 2 to 8 days, depending on the patient's condition and the effectiveness of therapy.

L-lysine escinat side effects

With individual hypersensitivity to escin in some patients, the following are possible: Allergic reactions: skin rash (papular, petechial, erythematous), itching, hyperemia of the skin of the face, lips, fever, urticaria; in isolated cases - Quincke's edema, anaphylactic shock. From the side of the central nervous system: headache, dizziness, tremor; in isolated cases - ataxia, short-term loss of consciousness. From the liver and biliary system: increased activity of transaminases and bilirubin. From the digestive system: nausea; in isolated cases - vomiting, diarrhea. From the side of the cardiovascular system: lowering blood pressure, increasing blood pressure, tachycardia, chest pain. From the respiratory system: isolated cases - a feeling of lack of air, shortness of breath, bronchial obstruction, dry cough. Local reactions: burning along the vein during administration, phlebitis, pain in the arm. Others: general weakness, chills, fever.

Drug interactions

The drug should not be used simultaneously with aminoglycosides because of the possibility of increasing their nephrotoxicity. In the case of a recent, prior to the appointment of L-lysine escinat, long-term anticoagulant therapy or, if necessary, the simultaneous administration of L-lysine escinat and anticoagulants, it is necessary to adjust the dose of the latter under the control of the prothrombin index. The binding of escin to plasma proteins is hampered by the simultaneous use of cephalosporin antibiotics, which can increase the concentration of free escin in the blood with the risk of developing side effects of the latter. The preparation contains ethyl alcohol 96%. It is necessary to take into account the possible interaction of alcohol with other drugs.

Overdose

fever, tachycardia, nausea, heartburn, epigastric pain.

Storage conditions

store at room temperature 15-25 degrees
keep away from children

Attention! The information is provided for informational purposes only. This instruction should not be used as a guide to self-medication. The need for prescription, methods and doses of the drug are determined exclusively by the attending physician.

general characteristics

International and chemical name: L-LYSINE AESCINAT

Structure: 1 ml of solution contains L- lysine (Lysines - a group of numerous antibodies. Bacteriolysins dissolve bacteria, cytolysins cause lysis of various cells in the body, etc.) escinatum (in terms of 100% substance) 0.001 g,

Additional substances: ethyl alcohol 96%, propylene glycol, water for injection.

Basic physical and chemical properties: clear, colorless solution;

Pharmacotherapeutic group

Capillary stabilizing agents. ATC code С05СХ 03 **.

Pharmacodynamics

Pharmacodynamics: The drug has anti-inflammatory, decongestant and analgesic effects. Escin reduces the activity of lysosomal hydrolases, which prevents the breakdown of mucopolysaccharides in the walls capillaries (Capillaries - the smallest vessels that penetrate organs and tissues. Connect arterioles with venules (the smallest veins) and close the circle of blood circulation) and in the connective tissue that surrounds them, and thus normalizes the increased vascular-tissue permeability and has an anti-exudative (decongestant), anti-inflammatory and analgesic effect. The drug increases vascular tone, has moderate immunocorrective and hypoglycemic effects.

Method of use and dosage

The daily dose for adults is 5-10 ml.
5-10 ml of the drug is diluted in 15-50 ml of sodium chloride, a solution for injections (Injection - injection, subcutaneous, intramuscular, intravenous, etc. introduction of small amounts of solutions (mainly drugs) into the tissues (vessels) of the body) 0.9% and administered intravenously only (intra-arterial administration is not allowed). In conditions that threaten the patient's life (acute period of traumatic brain injury, intra- and postoperative swelling of the head and spinal cord (Spinal cord - the department of the central nervous system, located in the spinal canal, is involved in the implementation of most reflexes. In humans, it consists of 31-33 segments, each of which has 2 pairs of nerve roots: the anterior ones are the so-called motor ones, along which impulses from the spinal cord cells are transmitted to the periphery (to skeletal muscle, vascular muscles, internal organs) and back - the so-called sensitive, through which impulses from the receptors of the skin, muscles, internal organs are transmitted to the spinal cord. The anterior and posterior roots, connecting with each other, form mixed spinal nerves. The most complex reflex reactions of the spinal cord are controlled by the brain) with symptoms of edema-swelling, large edema due to common injuries of soft tissues and musculoskeletal system), the daily dose is increased to 10 ml twice a day. The maximum daily dose for adults is 25 ml.
The duration of the drug use is 2 - 8 days, depending on the effectiveness of therapy.

Children: In children, a single dose is administered at the rate of: 1-5 years - 0.22 mg of L-lysine aescinat per kg of body weight; 5-10 years -0.18 mg L-lysine aescinat per kg of body weight; 10 years and older - 0.15 mg L-lysine aescinat per kg of body weight. The drug is administered 2 times a day. The duration of the course is from 2 to 8 days, depending on the patient's condition and the effectiveness of therapy.

Side effects

With individual sensitivity of escin in some patients, allergic reactions are possible in the form of a skin rash, hives (Hives - a disease characterized by the formation of limited or widespread itchy blisters on the skin and mucous membranes), angioedema.

Indications for use

Post-traumatic, intra- and postoperative edema of any localization: severe edema of the brain and spinal cord, including with intracranial hemorrhages, increased intracranial pressure and edema-swelling phenomena; edema of soft tissues with the involvement of the musculoskeletal system, accompanied by local disorders of their blood supply and pain syndrome (Pain syndrome - a painful subjective sensation that appears due to the impact on the body of superstrong or destructive stimuli. Distinguish pain syndromes of the head, face, mouth, back, etc.); edematous pain syndromes of the spine, trunk, extremities; severe violations of the venous circulation of the lower extremities in acute thrombophlebitis (Thrombophlebitis - venous disease characterized by inflammation of the venous wall and thrombosis. The onset of thrombophlebitis is preceded by inflammation of the vein - phlebitis and periphlebitis)accompanied by edematous-inflammatory syndrome.

Interaction with other drugs

When treating L-lysine with escinat, it is possible to prescribe other drugs if indicated (anti-inflammatory, analgesics (Analgesics - medicines that relieve or eliminate pain. Opium preparations, its alkaloids, their synthetic substitutes are called narcotic analgesics; analgin, paracetamol, acetylsalicylic acid and others - non-narcotic analgesics), antimicrobial). The drug should not be used simultaneously with aminoglycosides because of the possibility of increasing their nephrotoxicity. If necessary, the simultaneous appointment of L-lysine aescinat and anticoagulants (Anticoagulants - medicinal substancesreducing blood clotting) the doses of the latter must be reduced (control of the prothrombin index). Binding escin to protein (Protein - natural high molecular weight organic compounds... Proteins play an extremely important role: they are the basis of the life process, participate in the construction of cells and tissues, are biocatalysts (enzymes), hormones, respiratory pigments (hemoglobins), protective substances (immunoglobulins), etc.) plasma (Plasma - the liquid part of the blood, which contains the formed elements (erythrocytes, leukocytes, platelets). According to changes in the composition of blood plasma, various diseases are diagnosed (rheumatism, diabetes mellitus, etc.). Medicines are prepared from blood plasma) worsens with simultaneous use antibiotics (Antibiotics - substances with the ability to kill microbes (or prevent their growth). Used as drugs that suppress bacteria, microscopic fungi, some viruses and protozoa, there are also antitumor antibiotics) the cephalosporin series, which can increase the concentration of free escin in the blood with the risk of developing side effects of the latter.

Features of use

In some patients with hepatocholecystitis, when the drug is prescribed, a short-term increase in activity is possible transaminase (transaminases - enzymes of the class of transferases, the reactions catalyzed by them carry out a connection between protein and carbohydrate metabolism), which does not constitute a threat to patients and does not require discontinuation of the drug. Experience of use in pregnant women and in women during the period lactation (Lactation - milk secretion by the mammary gland) no.

General product information

Conditions and shelf life: Store out of the reach of children, protected from light at a temperature of 15-25 ° C. Shelf life is 2 years.

Terms of sale: On prescription

Packaging: 10 ampoules of 5 ml in a box

Manufacturer.Corporation "Arterium".

Location.01032, Ukraine, Kiev, st. Saksaganskogo, 139.

Website.www.arterium.ua

This material is presented in free form based on the official instructions for the medical use of the drug.